Rubicon Research profit and loss

Latest FY26

Revenue: ₹1,754cr
EBITDA: ₹400cr
Net profit: ₹247cr
EPS: ₹15.52

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026

Expenses
	1,936	1,754
	12.8	7.7
	1,949	1,762
	635	615
	110	91.3
	−123	−150
	284	256
	40.8	42.2
	50.8	45.3
	580	541
	1,577	1,441
	450	400
	399	355
Profit
	371	321
	371	321
	103	85.3
	−19.7	−11.5
	83.1	73.8
	288	247
	288	247
	−8.9	3.0
	279	250
	288	247
Per share
	₹17.74	₹15.52
	₹17.56	₹15.31
Other comprehensive income — detail
	−8.9	3.0
	−0.5	−1.1
	−0.1	−0.3
	−8.5	3.8
	—	250
Per share — as-filed variants
	₹17.74	₹15.52
	₹17.56	₹15.31
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,314	1,198
	67.9%	68.3%
Adjusted (ex-exceptional items) — derived
	371	321
	288	247
	₹17.74	₹15.52

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

RUBICON₹1,564.00

Rubicon Research Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSHILPAMED SPARC STAR SUPRIYA PARKHOSPS THYROCARE METROPOLIS MARKSANSMcap ₹25,820 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	1,754.0	1,935.8
Other Income	7.7	12.8
Total Income	1,761.7	1,948.6
Expenses
+ Cost of Materials Consumed	615.1	634.9
+ Purchases of Stock-in-Trade	91.3	110.0
+ Changes in Inventories	-150.4	-122.8
+ Employee Benefit Expense	256.3	283.8
+ Finance Costs	42.2	40.8
+ Depreciation & Amortisation	45.3	50.8
+ Other Expenses	541.4	579.7
Total Expenses	1,441.1	1,577.2
EBITDA	400.2	450.2
EBIT	355.0	399.4
Profit
PBT before Exceptional Items	320.5	371.4
Pretax Income	320.5	371.4
+ Current Tax	85.3	102.9
+ Deferred Tax	-11.5	-19.7
Tax Expense	73.8	83.1
Net Income	246.7	288.2
+ Net Income — Continuing Ops	246.7	288.2
+ Other Comprehensive Income	3.0	-8.9
Total Comprehensive Income	249.7	279.3
Net Income to Common	246.7	288.2
Per Share
Basic EPS	15.52	17.74
Diluted EPS	15.31	17.56
Other Comprehensive Income — detail
+ Other Comprehensive Income	3.0	-8.9
+ Items NOT to be Reclassified to P&L	-1.1	-0.5
+ Tax on Items NOT to be Reclassified	-0.3	-0.1
+ Items to be Reclassified to P&L	3.8	-8.5
Comprehensive Income — Owners of Parent	249.7	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	15.52	17.74
Diluted EPS — Continuing Operations	15.31	17.56
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,197.9	1,313.7
Gross Margin %	68.30	67.86
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	320.5	371.4
Net Income Adj (tax-effected)	246.7	288.2
EPS Adj	15.52	17.74
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00
Paid Up Equity Capital	16.5	16.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.